Objective: The relatively modest benefit of vasomotor symptom relief in clinical trials of isoflavones may reflect once-daily dosing and low percentages of participants who are able to metabolize daidzein into equol, a potentially more biologically active isoflavone. This pilot study examined whether symptom reduction was greater with more frequent administration and with higher daily doses. In addition, we explored possible effect modification by equol producer status.
H ot flashes occur in an estimated 50% to 80% of periand postmenopausal women in the United States, 1<4 and 20% to 30% of women seek medical treatment of these symptoms. 3<5 Exogenous hormone therapy (HT) is highly effective for symptom relief, 6, 7 but results from recent randomized clinical trials indicate that HT risks may outweigh benefits for many women. 8<11 Consequently, HT use has declined sharply since 2002, 12, 13 and women are seeking alternatives such as supplements containing isoflavones. 14<17 Several recent reviews and meta-analyses of randomized clinical trials assessing the effectiveness of isoflavones for vasomotor symptom (VMS) reduction 18<21 indicate an overall beneficial effect. However, results across studies are mixed, probably attributed in part to differences in factors such as participant eligibility criteria (eg, minimal number of hot flashes), as well as the dose and composition of isoflavone treatments. Estimates of improvement in VMS frequency ranged from approximately 20% to 60% (lower than the 80%-90% seen with HT), 6 and Guttuso 19 found that only 3 of 14 trials demonstrated a clinically meaningful reduction, defined as a decrease of at least two hot flashes per day.
The comparatively modest benefit of isoflavones on VMS reduction may reflect the once-daily dosing frequency used in most trials, despite isoflavones' relatively short half-life of 6 to 12 hours. 18, 22, 23 A recent National Institutes of Health workshop recommended considering frequency of administration when designing soy intervention trials. 24 Several trials have used dosing frequencies higher than once daily 25<30 ; however, to our knowledge, only two trials to date 25, 30 have examined multiple dosing frequencies simultaneously.
In addition, equol, a metabolite of the isoflavone daidzein, may be more biologically active than daidzein 31<34 owing to its greater affinity for estrogen receptors. 35, 36 Equol also is cleared more slowly from plasma than daidzein and thus may have longer-lasting effects. 35 This suggests that isoflavones' efficacy for VMS reduction may be higher in those able to produce equol. 18 Moreover, in contrast to Asian populations, only about 20% to 30% of Westerners produce equol, 35, 37 which could explain the modest effects seen in most trials on Western women. To date, effect modification by equol producer status has not been studied well and represents an important area for research. 18, 31, 38, 39 To provide preliminary data on these questions, we conducted a pilot randomized clinical trial to explore (1) whether the hot flash intensity score (hot flash frequency Â severity) differs depending on isoflavone dosing frequency and total daily dose, and (2) whether the impact of total daily dose or dosing frequency on the hot flash intensity score is greater in equol producers than in nonproducers.
METHODS

Study population and eligibility criteria
Participants were late perimenopausal women (3-11 consecutive months of amenorrhea), postmenopausal women (12 consecutive months of amenorrhea with no other cause), 40 or women who had hysterectomy but had at least one ovary, aged 40 to 69 years, and reported experiencing a mean of five or more moderate/severe hot flashes per day in the past week. This frequency/severity criterion was consistent with other studies 26,41<43 and balanced participant representativeness 44 with the ability to detect a treatment effect 18 (eg, avoiding a floor effect due to low baseline frequency). Additional criteria included willingness to record the intensity and time of each hot flash in daily diaries and to maintain current exercise and dietary patterns during the study. Exclusion criteria included bilateral oophorectomy or other iatrogenically induced menopause as in prior studies, 18, 26, 27, 45, 46 medical conditions or medications that may affect VMS or isoflavone metabolism (eg, use of antibiotics in the past 3 mo), and having soy allergy or requiring a specialized diet. Women who were nonadherent during the study run-in phase (defined as completing fewer than 80% of daily diary entries or using fewer than 80% of study pills), had fewer than a mean of five or more moderate/ severe hot flashes per day, or changed their medications during the run-in phase also were ineligible. During the run-in phase, no woman declined randomization owing to adverse effects that were possibly isoflavone-related, such as nausea or rashes.
The goal was to recruit equal numbers of equol producers and nonproducers, despite the anticipated higher percentage of nonproducers in the population, to compare isoflavone effectiveness in producers and nonproducers. After the equol nonproducer sample size target had been met, women determined to be nonproducers during the run-in phase were not asked to participate further. The study was approved by the Institutional Review Board at the University of Massachusetts Medical School (UMMS).
Recruitment and randomization
Participants were recruited through multiple sources and strategies, including advertising in newspapers, radio, and television; UMMS intranet messages and posters; worksite presentations; a public symposium at UMMS; health fairs and other community events; UMMS provider referrals; Registry of Motor Vehicle Electronic Billboard; and direct mailings. Participants were enrolled between June 2006 and July 2009. After initial eligibility had been established in a telephone interview, women completed an in-person visit at UMMS, which included provision of an informed consent form, confirmation of baseline eligibility, and collection of baseline data. Participants entered a 2-week run-in phase, during which they took placebo capsules on days 1 to 7, and 100-mg isoflavone capsules on days 8 to 14. This permitted the assessment of adherence to study capsules, isoflavone-related adverse effects, and equol producer status. Women also completed the daily hot flash diary to confirm eligibility and to provide baseline data on hot flash frequency and intensity. The remaining eligible women underwent a 7-day washout period to eliminate any effects of isoflavones used during the run-in phase.
Randomization to study arm was stratified by equol producer status. Separately for producers and nonproducers, Stata's ralloc command 47 was used to generate a sequence of group assignments randomly permuted in blocks of nine. The sequences for producers and nonproducers were uploaded into two Access databases, which were given to the study pharmacist who dispensed study capsules to participants.
Study treatments
The original study design involved nine treatment cells per equol producer stratum: three total daily doses (placebo, 100 mg/d, and 200 mg/d) crossed with three dosing frequencies (once daily, twice daily, and thrice daily). Owing to unanticipated recruitment-related challenges, particularly in identifying equol producers, the number of treatment cells per equol producer stratum was reduced to four midway through recruitment: placebo (twice daily), 200 mg once daily, 100 mg twice daily (200 mg total daily dose), and 66 mg thrice daily (200 mg total daily dose).
In addition, 42 women in the original protocol inadvertently received one third of the target dose owing to unclear prescription information, which led to inaccurate bottle labeling such that these participants took one tablet instead of the three tablets comprising a dose. As a result, the total daily doses in the study included placebo, 33 mg, 66 mg, 100 mg, and 200 mg. Also, equol producer status was not determined in three participants because of inadequate isoflavone consumption during the second run-in week; these women were omitted from analyses of effect modification by equol producer status. The treatment duration for all cells was 12 weeks.
All study capsules, including placebo, were identical in appearance to ensure blinding. Isoflavone capsules contained Novasoy 400, a soy-based isoflavone concentrate extracted to maintain the ratio of isoflavones, as well as aglycone and glycoside isoforms found in soybeans and unfermented soy foods, produced under current food Good Manufacturing Practices. 48<50 Archer Daniels Midland (ADM) manufactured and donated the capsules, and certified that the isoflavone tablets passed tests for quality assurance and control, including total isoflavone content, microbiology, and stability properties. A subsample of capsules (100 units of placebo, 300 units of 33 mg, and 300 units of 50 mg) was sent to an independent laboratory (Plant Bioactives Analytical) to confirm total isoflavone amounts (see Table 1 for capsule compositions, including calculated levels of aglycone equivalents) and to check for impurities, including heavy metals, disintegration, and bioactive components. The placebo was assayed for isoflavones and four heavy metals (arsenic, mercury, lead, and cadmium). The soy product (33 and 50 mg) was assayed for the variability of total isoflavone content (with a sample of 36; six tablets per concentration), as well as the estrogenic compounds estradiol, estrone, estriol, ethynylestradiol, and tamoxifen. The National Center for Complementary and Alternative Medicine accepted ADM's certification of pesticides, heavy metals, and product stability in March 2006.
Determination of equol producer status
At the completion of isoflavone consumption on the second week of the run-in phase, participants provided a first-morningurine sample, which was analyzed to determine equol producer status as follows. Urine samples (4 mL) were analyzed for equol and daidzein by gas chromatographyYmass spectrometry, as described previously. 51 A deuterated internal standard was used for each target compound. The interassay coefficients of variation were less than 15.0% for equol and daidzein. The limit of quantitation for all isoflavone targets was 5.0 ng/mL in urine. Women with urinary equol concentrations of 90 ng/mL or higher were defined as equol producers. 52 Participants who were determined by pill counts not to be compliant were asked to repeat the process.
Measures
After the run-in phase, participants completed daily hot flash diaries for 12 weeks and repeated in-person assessments on weeks 9 and 15. The outcome measure was hot flash in-tensity score, 53 computed as the weighted sum of hot flashes, weighting each hot flash by its intensity (1, mild; 2, moderate; 3, severe/very severe). Daytime and nighttime hot flashes (night sweats) were considered separately. Women recorded hot flashes and associated bother (1, not at all bothered; 4, extremely bothered) on a daily basis during the 12 weeks of treatment and returned the diaries by mail each week. Weekly mean scores were computed to smooth out day-to-day variability, as in a previous study. 54 Information on sociodemographic characteristics, menopause status, medication use, health behaviors (smoking and body mass index), dietary soy consumption, perceived stress, 55 and menopause-related quality of life was collected at baseline visit. Scales for the latter included Menopause-Related Quality of Life, 56 the Greene Climacteric Scale, 57 and the Hot Flash Related Daily Interference Scale. 58 Soy consumption also was measured at the 9-week and 15-week visits. Adherence to study medication was assessed by capsule count on weeks 9 and 15. In addition, participants received at least two safety assessment calls, which also assisted in participant retention. All data collectors and data entry staff were blinded to treatment assignment.
Statistical methods
Equol producers and nonproducers were compared on baseline characteristics, using frequencies and Fisher's exact tests for categorical variables, and means (SDs) and Wilcoxon rank sum tests for continuous variables.
To assess the effects of isoflavone total daily dose and dosing frequency on hot flashes, we modeled weekly hot flash intensity score using linear mixed modeling 59 as a function of week (follow-up weeks 1 through 12, treated as categorical to allow for nonlinear trajectories) and treatment arm, with adjustment for baseline hot flash intensity score to account for possible regression to the mean. 60 To examine whether doseand frequency-related differences varied by equol producer status, we added equol producer status and its interaction with treatment arm to the models. Scores were transformed as log[(follow-up score + 1) / (baseline score + 1)], as in the study by Avis et al, 61 to obtain normally distributed outcomes, and results were backtransformed to percent change since baseline for graphical presentation. Daytime and nighttime scores were modeled separately. Parallel models were estimated for absolute change in daytime plus nighttime hot flash frequency to explore whether clinically meaningful reductions (Q2 per day) occurred.
To avoid small cell counts, we collapsed the total daily doses 33 and 66 mg/day, the total daily doses 100 and 200 mg/day, and twice-daily and thrice-daily dosing, as indicated by preliminary analyses. In addition, all placebo cells were combined into a single group. We also considered the two dimensions of treatmentVtotal daily dose and dosing frequencyVseparately rather than jointly to increase cell counts. Adjustment for dosing frequency had little effect on dose-related associations with hot flash scores, and vice versa; in addition, including an interaction between dose and frequency did not improve model fit appreciably (data not shown). Consequently, results for dose and frequency are presented separately.
On sensitivity analyses, models were rerun on the subset of adherent participants, defined as those taking 80% or more of study pills according to self-report; results were similar (data not shown), probably owing to the high rate of adherence (83.6%). Additional sensitivity analyses imputed the last-observation-carried-forward method for missing weekly hot flash data; results were similar (data not shown). We also adjusted for several baseline characteristics predictive (P G 0.05) of change in daytime or nighttime hot flash intensity score: perceived stress, the Menopause-Related Quality of Life summary score, bother from hot flashes, and menopause status. Adjusted results were generally similar (data not shown) and based on a smaller sample size because of missing covariate data; thus, we present primarily unadjusted results. All were intention-to-treat analyses. Because this was a pilot study, P values were not adjusted for multiple comparisons.
RESULTS
As seen in the CONSORT diagram ( Fig. 1) , 130 eligible women agreed to participate and were randomized: 76 were equol nonproducers, 51 were equol producers, and 3 had unknown equol producer status. Among nonproducers, 24 were randomized to placebo; 15 were randomized to a low dose (33-66 mg) and 37 were randomized to a high dose (100-200 mg); and 16 were randomized to once-daily dosing and 36 were randomized to more frequent dosing. Among equol producers, 14 were randomized to placebo; 10 were randomized to a low dose and 27 were randomized to a high dose; and 12 were randomized to once-daily dosing and 25 were randomized to more frequent dosing. Two women did not provide follow-up data and thus were excluded from all primary analyses; both were equol nonproducers, both were randomized to a 200-mg total daily dose, one was randomized to oncedaily dosing, and the other was randomized to twice-daily dosing.
Baseline characteristics by equol producer status are presented in Table 2 . Among producers, none was assigned to 100 mg/day and a higher percentage was assigned to 200 mg/day, compared with nonproducers, because a larger proportion of producers were enrolled after the simplification of the study design. Other statistically significant differences included a lower percentage of producers reporting VMS benefit from antidepressant medication, a higher percentage of those who were late perimenopausal and had a corresponding lower mean age, and a lower Greene Climacteric Scale vasomotor subscale score. None of these characteristics was significantly associated with baseline-adjusted daytime or nighttime hot flash intensity. No other differences between equol producers and nonproducers were statistically significant. On average, women reported 7.2 daytime hot flashes per day and 2.9 nighttime hot flashes per day, with a mean bother level of 3.1 (moderately bothered). Mean soy consumption was low at below 1.5 servings per week; consumption remained stable during the study period, with a mean (SD) within-woman change in number of foods consumed at least twice per month of j0.05 (2.7). Equol producers and nonproducers did not differ in urinary concentration of daidzein, but as expected, producers had significantly higher concentrations of equol; all equol nonproducers in this study had urinary equol concentrations below the level of quantitation (5 ng/mL).
Among the 128 women with any follow-up data, retention (defined as returning Q80% of follow-up diaries) was 90.6% overall, ranging from 83.9% in the high-dose group to 97.4% in the placebo group (exact P = 0.054), and from 85.3% in the high-frequency group to 97.4% in the placebo group (exact P = 0.14). Adherence to study capsules (defined as taking Q80% of capsules according to self-report) ranged from 75.8% in the high-dose group to 92.9% in the low-dose group (exact P = 0.09), and from 80.3% in the high-frequency group to 89.5% in the placebo group (exact P = 0.50). On average, 49.6 (17.2) days elapsed between the baseline and the start of follow-up, with no statistically significant differences by total daily dose (P = 0.59) or by dosing frequency (P = 0.92). During the runin phase, 16 women (12.3%) reported at least one adverse effect that was possibly related to isoflavone consumption, including nausea, diarrhea, heartburn, breast tenderness, or rash. The percentage of participants reporting any of these adverse effects during study follow-up was 34.4% overall; 34.2% for women randomized to placebo; 46.4% for women randomized to 33 to 66 mg/day and 29.0% for women randomized to 100 to 200 mg/day (exact P = 0.24); and 41.4% for women randomized to once-daily dosing and 31.1% for women randomized to twice-daily to thrice-daily dosing (exact P = 0.62). Furthermore, 18.8% of participants reported an antibiotic prescription during follow-up, with no significant differences by total daily dose or by dosing frequency. Figure 2A presents percent change in daytime hot flash intensity scores by total daily dose, accounting for withinwoman correlation. Declines tended to be largest for the 100to 200-mg group, but smallest in the 33-to 66-mg group rather than in the placebo group. Dose-related differences were not statistically significant overall (P = 0.19). Corresponding results for nighttime hot flash intensity scores (Fig. 2B) showed a similar pattern, with wider and statistically significant (overall P = 0.02) differences between the dose groups, particularly the 33-to 66-mg group and the 100-to 200-mg group (pairwise difference P = 0.006). The mean absolute change in daytime plus nighttime hot flash frequency was j2.4 for placebo, j0.9 for 33 to 66 mg, and j3.3 for 100 to 200 mg, with a mean difference of 2.4 for high versus low dose.
Change in hot flash intensity scores by total daily dose
Change in hot flash intensity scores by dosing frequency
Analogous results for dosing frequency versus daytime hot flash intensity scores are presented in Fig. 3A . Declines tended to be largest for the twice-daily to thrice-daily group, and smallest for the once-daily group. Dosing frequencyY related differences were not statistically significant (P = 0.74), however, and were smaller in magnitude than corresponding differences for total daily dose. Patterns in nighttime hot flash intensity scores (Fig. 3B) were consistent, with larger frequency-related differences (P = 0.06) than for daytime scores, particularly for the twice-daily to thrice-daily group versus the once-daily group (P = 0.02). The mean absolute change in daytime plus nighttime hot flash frequency was j2.3 for placebo, j2.5 for once-daily dosing, and j2.6 for twice-daily to thrice-daily dosing.
Effect modification by equol producer status
Separation between dose groups in daytime hot flash intensity scores was somewhat larger for equol producers than for nonproducers ( Fig. 4A ), but effect modification by equol producer status was not statistically significant (P = 0.26 for dose Â equol producer status). Adjustment for covariates reduced the equol producerYrelated difference in the highest dose, from j48.1% for producers versus j39.3% for nonproducers (P = 0.21) to j41.5% for producers versus j42.8% for nonproducers (P = 0.87; adjusted P = 0.99 for dose Â equol producer status). The pattern was similar for nighttime hot flash intensity scores (Fig. 4B) , with greater between-dose differences among equol producers (P = 0.02) than among nonproducers (P = 0.40), owing in part to the lack of decline among equol producers randomized to 33 to 66 mg. Effect modification by equol producer status was not statistically significant, however (P = 0.45). The impact of adjustment for covariates on dose-related differences within the equol producer stratum was relatively small (adjusted P = 0.28 for equol Â dose). For both daytime and nighttime hot flash intensities, equol producers had consistently larger declines than nonproducers only in the subset of women randomized to 100 to 200 mg, although these differences by equol producer status were not statistically significant (P = 0.21 and P = 0.53, respectively).
Between-group differences in daytime hot flash intensity scores for dosing frequency (Fig. 4C) were somewhat larger for equol producers than for nonproducers, but effect modification was not statistically significant (P = 0.23). Adjustment for covariates reduced the equol producerYrelated difference in the highest frequency, from j49.5% for producers versus j34.1% for nonproducers (P = 0.04) to j38.0% for producers versus j37.6% for nonproducers (P = 0.90; adjusted P = 0.97 for dose Â equol producer status). Results for nighttime hot flash intensity scores (Fig. 4D ) were similar (P = 0.53 for frequency Â equol producer status), with little impact from adjustment for covariates.
DISCUSSION
Analyses from this pilot study suggest a greater percent reduction in both daytime and nighttime hot flash intensity scores with a high isoflavone dose, as seen in previous studies. 18 A total daily dose of 33 to 66 mg, however, did not confer benefits compared with placebo, consistent with results from the study by Ishiwata et al, 30 where the low-dose/lowfrequency group had the lowest symptom declines. The mean decline in total hot flash frequency was 2.4 per day greater for the 100-to 200-mg dose than for the 33-to 66-mg dose, a clinically meaningful difference. 19 For dosing frequency, percent declines in hot flash intensity tended to be largest for the twice-daily to thrice-daily group, but smallest for the oncedaily group, again consistent with Ishiwata et al. 30 Moreover, frequency-related differences were smaller than dose-related differences for both daytime and nighttime scores. Differences in absolute decline in total hot flash frequency between frequency groups, however, did not exceed the clinically significant cutoff of two or more per day. 19 For both dose and frequency, between-group differences were larger for nighttime scores than for daytime scores. The advantage of being an equol producer rather than a nonproducer was confined primarily to the high-dose and high-frequency groups, and this effect modification by equol producer status was not large enough to be statistically significant owing in part to small sample sizes.
Almost all prior trials of isoflavones and hot flashes have focused on the role of dose, 18 and most of these have used once-daily dosing. Among trials examining dosing frequencies higher than once daily, only two trials have compared multiple frequencies directly. Ishiwata et al 30 found improvements in vasomotor score in women randomized to S-equol thrice daily compared with placebo, but no differences versus placebo for women randomized to once daily; total daily dose, however, was confounded with frequency such that women randomized to greater dosing frequency also received a higher dose. Washburn et al 25 found greater improvements in hot flash severity for twice-daily dosing, but not for once-daily dosing, versus placebo. Our results, although not always statistically significant, are consistent. The advantage of more frequent dosing may result from better maintenance of isoflavone or equol levels over time. Pharmacokinetic analyses of equol indicate that twice-daily dosing is sufficient to maintain steady plasma levels. 62 Regarding the role of equol, an observational study in Japan noted milder hot flashes among equol producers than among nonproducers, 63 and several trials found that equol administration reduced hot flashes, 28<30 even among equol nonproducers. 28 Ishiwata et al 30 also assessed effect modification by equol producer status and found that receiving equol thrice daily reduced VMS compared with placebo, but only in nonproducers. In contrast, two other trials that used a supplement with a combination of daidzein, genistein, and glycitein found effect modification in the opposite direction (ie, larger reductions in hot flashes among equol producers). 64, 65 The current study, which also administered a combination of daidzein, genistein, and glycitein, found results similar to the latter trials. Differences across studies may reflect both type of supplementation (ie, daidzein vs equol) and participants' typical consumption of isoflavones. All three studies of effect modification by equol producer status cited above were conducted in Japanese or Taiwanese women, where isoflavone consumption tends to be relatively high compared with Western populations. 66 Another study also suggests that early-life exposure to isoflavones is necessary for later-life equol production capability. 67 In combination, however, these results suggest the importance of equol in reducing VMS, either through direct supplementation or through conversion of daidzein into equol.
Limitations of this study include its pilot nature and, consequently, small sample sizes. Cell sizes were too small for a well-powered examination of the interaction of total daily dose and dosing frequency (eg, to test whether 100-200 mg/d is significantly more effective when spread out over multiple administrations than when taken all at once). In addition, we did not have sufficient numbers of women randomized to placebo to compare different dosing frequencies and thus cannot examine whether dosing frequency per se, in the absence of isoflavone administration, affects hot flash intensity scores. We also did not measure serum or urinary equol during follow-up. As a result, despite the verification of adherence and thus daidzein exposure via capsule counts, safety monitoring calls, and self-reported capsule consumption in diaries, each participant's actual exposure to equol is unknown owing to between-person variability in the efficiency of the conversion of daidzein into equol. 68, 69 Given the probable range in equol levels, the magnitude of exposure in some participants may have been insufficient for hot flash reduction even among equol producers.
The study had a number of strengths, however. We included perimenopausal and postmenopausal women because hot flashes peak in the years near the final menstrual period. 70 Hot flash data were collected prospectively using daily diaries, as required by the Food and Drug Administration, 19 and daytime and nighttime hot flashes were measured and analyzed separately. The duration of intervention and follow-up was 12 weeks, consistent with prior studies and recommendations. 18, 71 Innovative features include an examination of both dosing frequency and effect modification by equol producer status. To date, only a few prior trials have compared multiple dosing frequencies. In addition, this was one of the few studies to stratify sampling and randomization by equol FIG. 4 . A: Percent change in daytime hot flash (HF) intensity, adjusted for baseline daytime HF intensity, by total daily dose and equol producer status weekly during the intervention. B: Percent change in nighttime HF intensity, adjusted for baseline nighttime HF intensity, by total daily dose and equol producer status weekly during the intervention. C: Mean percent change in daytime HF intensity, adjusted for baseline daytime HF intensity, by dosing frequency and equol producer status weekly during the intervention. D: Percent change in nighttime HF intensity, adjusted for baseline nighttime HF intensity, by dosing frequency and equol producer status weekly during the intervention. producer status and to include non-Asian women, who tend to have low typical and early-life isoflavone consumption.
CONCLUSIONS
This pilot study on women with typically low isoflavone consumption provides preliminary evidence that isoflavone administration at least twice daily may provide greater hot flash relief than isoflavone administration once daily. Any benefit from more frequent dosing, as well as from higher total doses, may occur primarily in equol producers. Larger studies, including an examination of the impact of dosing frequency on the placebo group, are needed to confirm and extend these findings.
